Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults.

Abuelazm, Hagar; Elsayed, Omar H; El-Mallakh, Rif S

Abuelazm, Hagar; Elsayed, Omar H; El-Mallakh, Rif S.

Affiliation

Abuelazm H; Mood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA.
Elsayed OH; Mood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA.
El-Mallakh RS; Mood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA.

Expert Rev Neurother ; 23(8): 751-756, 2023.

Article in En | MEDLINE | ID: mdl-37458003

Subject(s)

Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; United States; Humans; Adult; Antipsychotic Agents/therapeutic use; Antipsychotic Agents/pharmacology; Bipolar Disorder/drug therapy; Depressive Disorder, Major/drug therapy; Dopamine/therapeutic use; Antidepressive Agents/therapeutic use

Key words

Bipolar disorder; depression; lumateperone; mood stabilizers; pharmacotherapy; treatment; type I bipolar; type II bipolar

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antipsychotic Agents / Bipolar Disorder / Depressive Disorder, Major Type of study: Clinical_trials / Risk_factors_studies Limits: Adult / Humans Country/Region as subject: America do norte Language: En Journal: Expert Rev Neurother Journal subject: NEUROLOGIA / TERAPEUTICA Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google